Multifunctional hyaluronic acid-based biomimetic/pH-responsive hybrid nanostructured lipid carriers for treating bacterial sepsis
Journal of Biomedical Science,
Journal Year:
2025,
Volume and Issue:
32(1)
Published: Feb. 11, 2025
Abstract
Introduction
The
application
of
biomimetic
and
stimuli-responsive
nanocarriers
displays
considerable
promise
in
improving
the
management
bacterial
sepsis
overcoming
antimicrobial
resistance.
Therefore,
study
aimed
to
synthesize
a
novel
hyaluronic
acid-lysine
conjugate
(HA-Lys)
utilize
attributes
synthesized
HA-Lys
with
Tocopherol
succinate
(TS)
Oleylamine
(OLA)
formulation
multifunctional
pH-responsive
HNLCs
loaded
vancomycin
(VCM-HNLCs),
combat
sepsis.
Methods
A
was
characterized
using
FTIR
1
H
NMR
spectroscopy.
Vancomycin-loaded
hybrid
nanosystems
(VCM-HNLCs)
were
prepared
through
hot
homogenization
ultrasonication
evaluated
for
particle
size,
polydispersity
index
(PDI),
zeta
potential
(ZP),
encapsulation
efficiency
(EE%).
In
vitro
biocompatibility
assessed
via
MTT
assay
red
blood
cell
hemolysis
test.
binding
affinity
TLR2
TLR4
measured
microscale
thermophoresis
(MST).
Drug
release
dialysis
bag
method.
Antimicrobial
activity
against
MRSA
efflux
pump
inhibition
also
determined.
Efficacy
demonstrated
an
MRSA-induced
mice
model.
Results
VCM-HNLCs,
produced
ultrasonication,
exhibited
size
(PS),
(EE%)
110.77
±
1.692
nm,
0.113
0.022,
−
2.92
0.210
mV,
76.27
1.200%,
respectively.
,
proven
by
cytotoxicity
studies.
VCM-HNLCs
targetability
human
Toll-like
receptors
(TLR
2
4)
as
validated
showed
twofold
reduction
MIC
values
at
physiological
pH
compared
bare
VCM
S.
aureus
48
h.
While
6.0,
reduced
fourfold
first
24
h
eightfold
subsequent
72
tested
strains.
Furthermore,
inhibitory
effects
pumps,
reactive
oxygen
species
(ROS),
lipopolysaccharide
(LPS)-induced
hyperinflammation.
model,
superior
efficacy
free
VCM,
significantly
eliminated
bacteria
improved
survival
rates.
Conclusions
Overall,
these
results
highlight
resistance
(AMR)
enhance
outcomes.
Graphical
Language: Английский
Current strategies against multidrug-resistant Staphylococcus aureus and advances toward future therapy
The Microbe,
Journal Year:
2025,
Volume and Issue:
unknown, P. 100281 - 100281
Published: Feb. 1, 2025
Language: Английский
A step forwarded on the in vitro and in vivo validation of rifabutin-loaded liposomes for the management of highly virulent MRSA infections
Journal of Controlled Release,
Journal Year:
2025,
Volume and Issue:
380, P. 348 - 361
Published: Feb. 8, 2025
Staphylococcus
aureus
(S.
aureus)
infections,
especially
methicillin
resistant
(MRSA),
constitute
an
alarming
public
health
issue
due
to
its
association
with
high
mortality,
morbidity,
and
hospitalization
costs.
The
increasing
antibiotic
resistance
biofilm-associated
infections
of
MRSA
prompted
the
discovery
novel
more
effective
therapeutic
strategies.
Our
team
has
been
working
on
alternative
therapies
against
S.
infections.
For
this,
we
have
repurposing
existing
antibacterial
drug,
rifabutin
(RFB),
through
a
nanotechnological
platform,
liposomes,
aiming
promote
preferential
targeting
infected
sites
maximizing
potential
effect.
RFB
formulations
commercial
strain
(MRSA
ATCC®-33592),
either
in
planktonic
or
biofilm
forms,
was
assessed.
displayed
higher
effects
towards
than
vancomycin
(VCM),
gold
standard
treatment
MBIC50
values
103
>
800
μg/ml,
respectively.
Moreover,
antimicrobial
effect
RFB-loaded
liposomes
demonstrated
be
lipid
composition-dependent
based
MIC50
values,
which
also
confirmed
by
confocal
laser
scanning
microscopy.
These
studies
supported
that
for
positively
charged
electrostatic
interaction
at
surface
occurs
without
internalization.
On
other
hand,
neutral
charge
internalization
within
observed.
this
liposomal
formulation
stable
human
plasma,
as
83
%
still
associated
24
h
after
incubation
37
°C.
proof
concept
assessed
systemic
murine
models
infection.
Therapeutic
survival
rates
were
evaluated
animals
induced
treated
free
forms
compared
negative
positive
controls.
lower
infection
model,
100
achieved
all
groups
under
study.
However,
model
only
group
incorporated
attained.
In
terms
bacterial
burden,
exhibited
levels
when
VCM,
even
using
dose:
20
vs
40
mg/kg
body
weight,
Overall,
constitutes
strategy
being
potentiated
nanoplatform.
Language: Английский
Liposomal nanoformulations of novel copper-based complexes exhibiting antimelanoma activity – In vitro and in vivo validation
International Journal of Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
unknown, P. 125643 - 125643
Published: April 1, 2025
Language: Английский
Preparation and evaluation of alizarin loaded liposomes for improved antibiofilm activities
Journal of Molecular Liquids,
Journal Year:
2024,
Volume and Issue:
unknown, P. 126545 - 126545
Published: Nov. 1, 2024
Language: Английский
Nanoformulations: Microscopic Soliders Targeting Biofilms and Defeating Bacterial Resistance
Journal of Microscopy and Ultrastructure,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 28, 2024
Abstract
Biofilms
are
organized
colonies
of
bacteria
surrounded
by
a
self-generated
polymeric
matrix
that
sticks
to
surfaces.
They
involved
in
wide
range
infections,
especially
chronic
and
device-related
diseases,
due
their
resistance
traditional
medicines
the
human
immune
system.
Nanoformulations
have
emerged
as
viable
technique
for
combating
biofilms
distinct
physicochemical
features,
which
improve
antimicrobial
drug
penetration,
stability,
targeted
administration.
This
review
focuses
on
most
recent
breakthroughs
nanoformulation
techniques
specifically
developed
inhibit
disrupt
biofilms.
Language: Английский